Clinical Trial Update: Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating paclitaxel, trastuzumab, and pertuzumab for metastatic HER2-positive breast cancer completed with posted results in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-08-03